The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Teralys Capital

Québec’s $122 million New Biopharmaceutical Strategy Includes $30 million for Genomics, May Include SR&ED Tax Credit Financing

The Province of Québec rolled out a new “biopharmaceutical strategy” Thursday that they say aims to provide “development support for biotech and biopharmaceutical firms.” The Roll-Out: The announcement was beautifully coordinated with the relevant constituencies, as illustrated by the near-immediate chorus of support: Génome Québec said thank-you for the $30 million, we’ll get right to work. Merck Frosst [...]

New Data Shows 70% of Canada’s Biotech Companies Have Under 12 Months’ Cash. BIOTECanada’s New Ask: Government Loans.

A Canwest story today highlights new BIOTECanada data showing 70% of survey respondents have under 1 year of cash, up from 50% in January.  FierceBiotech picked it up as well, guaranteeing a full dose of international attention.   Even though the remaining 30% of respondents likely include some with big recent successes — Bioniche, Allostera and Zymeworks – and some with creative [...]

$700 Million Close Opens the Doors at Teralys Capital

Teralys Capital, the fund-of-funds announced in Quebec’s budget in March, actually closed on its $700 million today and “is now ready to move ahead with its mandate to finance private venture capital funds that invest in technology companies in the life sciences, information technology and clean technology sectors.”  (I guess the extra $125 million they were [...]

What You Missed While You Were at BioFinance

A lot to catch up on over the last few days… A professor in Hong Kong says don’t relax just because flu cases outside of Mexico have been mild — more spread equals more chances for further mutation. You think Biden had a bad public speaking week?  Check this one out from the Environment Minister [...]

Follow

Get every new post delivered to your Inbox.

Join 93 other followers